TO THE EMPLOYEES OF SOPHARMA AD

Dear Madams and Sirs,

In relation with the requirement of art. 151, par. 3 of POSA, with the current letter we present a draft tender offer for the purchase of all shares of the other shareholders of Momina Krepost AD by the majority shareholder Sopharma AD. The following attachments have been added to the draft tender offer:

1. Current certificate of registration in the Commercial Register of the tender offeror Sopharma AD;

SOPHARMA AD hereby informs that from 26 March 2015 up to and including 1 April 2015 the Company bought 664 own shares representing 0.00049% of the share capital of the Company, at a total value of 2310.8 BGN on the Bulgarian Stock Exchange, the average price per share was 3.48 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 163 820, representing 3.83% of the share capital of the Company.

Sopharma AD notifies that for March 2015 the Company recorded a decrease of sales revenues of 7% compared to the same month of 2014, including 32% increase of domestic sales and 21% decrease of export sales.

For the three months of this year, revenues from sales decreased by 21% compared to the same period of 2014, including 20% increase of domestic sales and a 35% decrease of export sales.

In March 2015 the subsidiary of Sopharma AD, Sopharma Ukraine EOOD, with a core business in trading with pharmaceutical products, increased its capital to 317 531 502 UAH.

Sopharma AD notifies that for April 2015 the Company recorded an increase of sales revenues of 2% compared to the same month of 2014, including 8% increase of domestic sales and 1% decrease of export sales.

For the four months of this year, revenues from sales decreased by 15% compared to the same period of 2014, including 16% increase of domestic sales and a 28% decrease of export sales.

Sopharma AD informs that the Board of Directors of Sopharma AD authorized the Executive Director of the company to undertake negotiations for the sale of the shares of Extab Corporation owned by Sopharma AD.

Sopharma AD informs that today Sopharma reached an agreement for the sale of 75% of the capital of Extab Corporation. After the transaction Sophama will remain a shareholder in the company with 5%.

SOPHARMA AD hereby informs that from 14 May 2015 up to and including 20 May 2015 the Company bought 3312 own shares representing 0.0025% of the share capital of the Company, at a total value of 10 274.19 BGN on the Bulgarian Stock Exchange, the average price per share was 3.10 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 167 132, representing 3.83% of the share capital of the Company.

SOPHARMA AD hereby informs that from 21 May 2015 up to and including 27 May 2015 the Company bought 2000 own shares representing 0.0015% of the share capital of the Company, at a total value of 6 130.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.07 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 169 132, representing 3.83% of the share capital of the Company.

Sopharma AD notifies that for May 2015 the Company recorded an increase of sales revenues of 3% compared to the same month of 2014, including 14% increase of domestic sales and 2% decrease of export sales.

For the five months of this year, revenues from sales decreased by 12% compared to the same period of 2014, including 16% increase of domestic sales and a 22% decrease of export sales.

The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that in order to achieve synergies in the Sopharma Group, optimization of the management of products in the domestic market and higher efficiency of resources, the team responsible for the products produced by Sopharma AD and intended for the free market (OTC products) in being transferred to Sopharma Trading AD. The management of both companies believes that this is a logical step in improving the performance and quality of the work of the Group.